Theratechnologies Inc (TSE:TH) had its target price decreased by analysts at Scotiabank from C$9.50 to C$9.25 in a report released on Friday. The firm presently has an “outperform” rating on the stock. Scotiabank’s price target would suggest a potential upside of 23.17% from the company’s current price.

Separately, National Bank Financial downgraded Theratechnologies from an “outperform market weight” rating to a “sector perform market weight” rating in a research report on Monday, July 3rd.

Theratechnologies (TSE:TH) opened at 7.51 on Friday. The company has a 50-day moving average of $7.54 and a 200-day moving average of $7.00. The company’s market cap is $558.86 million. Theratechnologies has a 52 week low of $2.61 and a 52 week high of $8.72.

TRADEMARK VIOLATION WARNING: This news story was first published by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another site, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this news story can be read at

Theratechnologies Company Profile

Theratechnologies Inc is a specialty pharmaceutical company. The Company addresses medical needs to promote healthy living among human immunodeficiency virus (HIV) patients. Its products include EGRIFTA and Ibalizumab. EGRIFTA (tesamorelin for injection) refers to tesamorelin and it is indicated for the reduction of excess abdominal fat in HIV infected patients with lipodystrophy.

Receive News & Ratings for Theratechnologies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.